These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32129956)

  • 1. Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab.
    Bettencourt MS
    J Drugs Dermatol; 2020 Feb; 19(2):132-136. PubMed ID: 32129956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
    Green L; Weinberg JM; Menter A; Soung J; Lain E; Jacobson A
    J Drugs Dermatol; 2020 Feb; 19(2):138-143. PubMed ID: 32129957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases.
    Armstrong A; Fried R; Koo J; Gottlieb A; Jackson A
    J Drugs Dermatol; 2023 Oct; 22(10):994-1000. PubMed ID: 37801526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and Sustained Improvement in a Patient With Plaque Psoriasis Switched to Brodalumab After Failing Treatment Clearance on Six Other Biologic Therapies.
    Haycraft K; Cooke L
    J Drugs Dermatol; 2020 Jan; 19(1):86-88. PubMed ID: 32023014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-17 treatment of psoriasis.
    Jinna S; Strober B
    J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brodalumab in the treatment of chronic plaque psoriasis.
    Gisondi P; Girolomoni G
    Expert Opin Biol Ther; 2020 Oct; 20(10):1175-1186. PubMed ID: 32463723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.
    Lebwohl M; Menter A; Lain E; Han G; Jacobson A
    J Drugs Dermatol; 2022 Apr; 21(4):354-370. PubMed ID: 35389586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL17 therapies for psoriasis.
    Silfvast-Kaiser A; Paek SY; Menter A
    Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recapture Rate of Brodalumab in Patients With a Lapse in Treatment.
    Lebwohl M; Cather J; Armstrong A; Van Voorhees A; Jacobson A
    J Drugs Dermatol; 2020 Apr; 19(4):384-387. PubMed ID: 32272515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging therapies in psoriasis.
    Leonardi CL; Gordon KB
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.